E-Freeze: Freezing of embryos in assisted conception

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
24/12/2015		[X] Protocol		
Registration date 29/12/2015	Overall study status Completed Condition category	[X] Statistical analysis plan		
		[X] Results		
Last Edited		Individual participant dat		
29/07/2024	Pregnancy and Childbirth			

Plain English summary of protocol

Current plain English summary as of 07/05/2019:

Background and study aims

In order for a woman to become pregnant, the fertilised egg must attach (implant) itself to the lining of the womb. In vitro fertilisation (IVF) is a technique used to help people with fertility problems to have a baby. During IVF, couples donate their own sperm and eggs (or use sperm and eggs from a donor). The egg is fertilised by the sperm outside of the body to create an embryo and then returned to the woman's womb to develop, approximately three days later (fresh embryo transfer). Although IVF has become more and more successful in recent years, there is still a relatively high failure rate. In many cases, some of the embryos are frozen so that they can be thawed out and used in IVF at a later date (frozen embryo transfer). The aim of this study is to find out the effectiveness and cost-effectiveness of using frozen embryo transfer three months after egg donation, compared to fresh embryo transfer, and whether the technique used has an effect of the health of the baby at birth.

Who can participate?

Couples undergoing their first, second or third round of IVF fertility treatment at fertility centres in the UK.

What does the study involve?

Couples are randomly allocated to one of two groups. At the start of the study, all participants donate sperm and eggs so that embryos can be created. For participants in the first group, three days after egg donation, the fertilised embryos are placed in the female participants' womb. For participants in the second group, the fertilised embryos are frozen, for later use. These embryos are then thawed three months after the egg donation and implanted into the female participants' womb. Women in both groups are monitored to find out how many become pregnant. For those who do, the health of the baby is assessed by the medical team at the time of birth.

What are the possible benefits and risks of participating?

There are no immediate direct benefits of taking part in the study, but participating will help to inform future fertility treatment in the UK. There are no additional risks to the standard risks involved with IVF.

Where is the study run from? Twelve fertility units in the Scotland and England (UK).

When is the study starting and how long is it expected to run for? March 2015 to January 2021 (updated 08/07/2020, previously: June 2020)

Who is funding the study? National Institute for Health Research (UK)

Who is the main contact?

1. Ms Christina Cole (public), christina.cole@npeu.ox.ac.uk (updated 08/07/2020, previously: Ms Fiona Goodgame (public), fiona.goodgame@npeu.ox.ac.uk) 2. Dr Abha Maheshwari (scientific), a.maheshwari@abdn.ac.uk

Previous plain English summary:

Background and study aims

In order for a woman to become pregnant, the fertilised egg must attach (implant) itself to the lining of the womb. In vitro fertilisation (IVF) is a technique used to help people with fertility problems to have a baby. During IVF, couples donate their own sperm and eggs (or use sperm and eggs from a donor). The egg is fertilised by the sperm outside of the body to create an embryo and then returned to the woman's womb to develop, approximately three days later (fresh embryo transfer). Although IVF has become more and more successful in recent years, there is still a relatively high failure rate. In many cases, some of the embryos are frozen so that they can be thawed out and used in IVF at a later date (frozen embryo transfer). The aim of this study is to find out the effectiveness and cost-effectiveness of using frozen embryo transfer three months after egg donation, compared to fresh embryo transfer, and whether the technique used has an effect of the health of the baby at birth.

Who can participate?

Couples undergoing their first, second or third round of IVF fertility treatment at fertility centres in the UK.

What does the study involve?

Couples are randomly allocated to one of two groups. At the start of the study, all participants donate sperm and eggs so that embryos can be created. For participants in the first group, three days after egg donation, the fertilised embryos are placed in the female participants' womb. For participants in the second group, the fertilised embryos are frozen, for later use. These embryos are then thawed three months after the egg donation and implanted into the female participants' womb. Women in both groups are monitored to find out how many become pregnant. For those who do, the health of the baby is assessed by the medical team at the time of birth.

What are the possible benefits and risks of participating?

There are no immediate direct benefits of taking part in the study, but participating will help to inform future fertility treatment in the UK. There are no additional risks to the standard risks involved with IVF.

Where is the study run from?

Twelve fertility units in the Scotland and England (UK).

When is the study starting and how long is it expected to run for? March 2015 to June 2020

Who is funding the study? National Institute for Health Research (UK)

Who is the main contact?

1. Ms Christina Cole (public)
christina.cole@npeu.ox.ac.uk

2. Dr Abha Maheshwari (scientific)
abha.maheshwari@abdn.ac.uk

Study website

https://www.npeu.ox.ac.uk/e-freeze

Contact information

Type(s)

Public

Contact name

Ms Christina Cole

Contact details

NPEU
Nuffield Department of Population Health
University of Oxford
Old Road Campus
Oxford
United Kingdom
OX3 7LF

_

christina.cole@npeu.ox.ac.uk

Type(s)

Scientific

Contact name

Dr Abha Maheshwari

Contact details

Aberdeen Maternity Hospital Foresterhill Aberdeen United Kingdom AB25 2ZL

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Freezing of embryos in assisted conception: a randomised controlled trial evaluating the clinical and cost-effectiveness of a policy of freezing embryos followed by thawed frozen embryo transfer, compared with a policy of fresh embryo transfer in women undergoing in-vitro fertilization.

Acronym

E-Freeze

Study objectives

The aim of this study is to determine if a policy of freezing embryos, followed by thawed frozen embryo transfer results in a higher healthy baby rate when compared with the current policy of transferring fresh embryos.

Ethics approval required

Old ethics approval format

Ethics approval(s)

North of Scotland Research Ethics Committee, 12/11/2015, ref: 15/NS/0114

Study design

Pragmatic multi-centre parallel-group randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Other

Participant information sheet

Health condition(s) or problem(s) studied

Infertility

Interventions

Couples will be randomly allocated to either the standard care or intervention arm.

Standard care arm: Women will undergo fresh embryo transfer on day 3 or 5 (after egg collection).

Intervention arm: All good quality embryos will be frozen and couples will undergo frozen thawed embryo transfer within 3 months of the egg collection process. Couples will attend for a clinic visit and additional monitoring visits before frozen embryo transfer is performed.

Data be collected using bespoke electronic data collection forms at 6 time points between consent and 6 weeks post delivery. An emotions questionnaire will also be completed both after consent and at embryo transfer to understand how couples are feeling. And an economic questionnaire will be used to understand time and travel expenses accrued during their treatment.

Intervention Type

Procedure/Surgery

Primary outcome measure

Health of the baby is determined by medical staff at the time of birth.

Secondary outcome measures

- 1. Live birth rate
- 2. Pregnancy rate (defined as positive pregnancy test 2 weeks after embryo transfer)
- 3. Clinical pregnancy rate (a pregnancy diagnosed by ultrasonic visualisation of one or more gestational sacs or definitive clinical signs of pregnancy; ectopic counts as clinical pregnancy; multiple gestational sacs count as one clinical pregnancy)
- 4. Ongoing pregnancy (pregnancy with presence of foetal heart beat)
- 5. Ovarian hyperstimulation syndrome (OHSS)
- 6. Miscarriage rate
- 7. Gestational diabetes mellitus (GDM)
- 8. Multiple pregnancy
- 9. Hypertensive disorders of pregnancy (comprising pregnancy induced hypertension; preeclampsia and eclampsia)
- 10. Antepartum haemorrhage
- 11. Preterm delivery (defined as delivery at <37 completed weeks)
- 12. Very preterm delivery (defined as delivery at <32 completed weeks)
- 13. Low birth weight (defined as weight < 2500 g at birth)
- 14. Very low birth weight (defined as < 1500 g at birth)
- 15. Large for gestational age (defined as birth weight >90th centile for gestation, based on standardised charts)
- 16. Small for gestational age (defined as less than 10th centile for gestational age at delivery)
- 17. Congenital anomaly (all congenital anomalies identified will be included)
- 18. Perinatal mortality (late as well as early neonatal deaths, up to 28 days after birth)
- 19. Evaluation of emotional state
- 20. Health economic outcome measures:
- 20.1. Costs to the health service of treatment, pregnancy and delivery care
- 20.2. Modelled long-term costs of health and social care, and broader societal costs

Overall study start date

01/03/2015

Completion date

Eligibility

Key inclusion criteria

Current participant inclusion criteria (as of 24/01/2018):

- 1. The female partner is between 18 and 42 years of age at the start of treatment (i.e. start of ovarian stimulation)
- 2. Couples who are undergoing their first second or third cycle of IVF/ICSI treatment
- 3. Both partners are resident in the UK
- 4. Both partners are able to provide written informed consent

Previous participant inclusion criteria

- 1. The female partner is between 18 and 42 years of age at the start of treatment (i.e. start of ovarian stimulation)
- 2. Couples who are undergoing their first cycle of IVF/ICSI treatment
- 3. Both partners are resident in the UK
- 4. Both partners are able to provide written informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

1.086

Total final enrolment

619

Key exclusion criteria

Couples in whom:

- 1. Donor gametes are used
- 2. Pre-implantation genetic diagnosis is performed
- 3. Elective freezing of all embryos is preferred or clinically indicated (e.g. severe risk of OHSS)

Date of first enrolment

01/01/2016

Date of final enrolment

30/04/2019

Locations

Countries of recruitment

England

Scotland

United Kingdom

Study participating centre Aberdeen Maternity Hospital

Aberdeen Fertility Centre Foresterhill Aberdeen United Kingdom AB25 2ZL

Study participating centre St Mary's Hospital

Department of Reproductive Medicine, 1st Floor Oxford Road Manchester United Kingdom M13 9WL

Study participating centre Sheffield Teaching Hospitals

Jessop Wing, Assisted Conception Unit Tree Root Walk Sheffield United Kingdom S10 2SF

Study participating centre King's College Hospital Assisted Conception Unit

Denmark Hill London United Kingdom SE5 9RS

Study participating centre

Princess Anne Hospital

Complete Fertility Centre Coxford Road Southampton United Kingdom SO16 5YA

Study participating centre Hewitt Fertility Centre

Crown Street Liverpool United Kingdom L8 7SS

Study participating centre Guy's and St Thomas' Assisted Conception Unit

11th Floor, Tower Wing Great Maze Pond London United Kingdom SE1 9RT

Study participating centre Hammersmith Hospital

IVF Hammersmith Du Cane Road London United Kingdom W12 0HS

Study participating centre Nurture Fertility

The East Midlands Fertility Centre Interchange Business Park Sandiacre Nottingham United Kingdom NG10 5QE

Study participating centre

Homerton Fertility Centre

Homerton Row London United Kingdom E9 6SR

Study participating centre Oxford Fertility Unit

Nuffield Department of Obstetrics and Gynaecology Oxford Business Park North Oxford United Kingdom OX4 2HW

Study participating centre Birmingham Women's Fertility Centre

Mindelsohn Way Birmingham United Kingdom B15 2TG

Sponsor information

Organisation

NHS Grampian

Sponsor details

Research & Development Foresterhill House Annexe Foresterhill Aberdeen Scotland United Kingdom AB25 2ZB

Sponsor type

Hospital/treatment centre

Website

http://www.nhsgrampian.org/nhsgrampian/gra_display_home_2015.jsp?p_applic=CCC&p_service=Content.show&pContentID=9298&

ROR

Organisation

University of Aberdeen

Sponsor details

Research Governance Office Foresterhill House Annexe Foresterhill Aberdeen Scotland United Kingdom AB25 2ZB

Sponsor type

University/education

Funder(s)

Funder type

Government

Funder Name

National Institute for Health Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

The research will be submitted for publication in high impact peer-reviewed scientific journals.

Intention to publish date

30/06/2021

Individual participant data (IPD) sharing plan

Applications for data sharing should be made to the NPEU CTU, using ctu@npeu.ox.ac.uk, with an accompanying protocol for the intended use of the data. This will be reviewed by the Trial Steering Committee or Data Controller if the TSC no longer exist. If approved, a Data Sharing Agreement will be compiled laying out the conditions to which the requestor must abide by. A cost may be incurred if the data requires additional work prior to sharing.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article		13/06/2019	17/06/2019	Yes	No
Statistical Analysis Plan		30/06/2020	02/07/2020	No	No
Results article		06/01/2022	10/01/2022	Yes	No
Funder report results		01/05/2022	24/05/2022	No	No
HRA research summary			28/06/2023	No	No
Results article		13/06/2024	29/07/2024	Yes	No